Pharmaceutics

Making Bone-Targeted Lipid Nanoparticles Modified with Alendronate for Delivering mRNA

Updated

Abstract

Post-conjugation modification of lipid nanoparticles results in significantly superior bone affinity compared to pre-conjugation.

  • Bone-targeting lipid nanoparticles (LNPs) were developed using two different alendronate modification strategies.
  • Hydroxyapatite binding assays indicated that LNPs from the post-conjugation method had stronger binding to bone than those from the pre-conjugation method.
  • Ex vivo experiments demonstrated that post-conjugation LNPs exhibited enhanced bone-binding capability over unmodified LNPs.
  • Optimized alendronate-functionalized LNPs showed efficient cellular uptake and functional mRNA translation in bone marrow stem cells with minimal cytotoxicity.
  • Studies in mice revealed preferential accumulation of alendronate-LNPs in bone tissues, with successful translation of GFP mRNA in these areas.
  • Histopathological analysis confirmed the biosafety of the formulated lipid nanoparticles.

Simplified

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free